Crispr Rallies As The First-Ever Gene-Editing Drug Faces The FDA
The Food and Drug Administration appears likely to approve Crispr Therapeutics' (CRSP) gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher. The bullish sentiment follows a "relatively benign" FDA advisory committee on Tuesday, Mizuho Securities analyst…
#crisprtherapeutics #crsp #fda #mizuhosecurities #salimsyed #gilblum #gilwolfe #universityatbuffalo #leerinkpartners #maniforoohar
